LPTX Leap Therapeutics Inc.

+0.02  (+1%)
Previous Close 1.65
Open 1.7
Price To Book 5.57
Market Cap 37174703
Shares 22,260,301
Volume 463,300
Short Ratio
Av. Daily Volume 361,147

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 interim data noted 46.7% ORR.
TRX518 in combination with gemcitabine chemotherapy or KEYTRUDA or Opdivo
Advanced solid tumors
Phase 1/2 data ESMO October 2018. 24% ORR.
Esophagogastric adenocarcinoma
Phase 1/2 data released December 14, 2018 noted 21.3% PR rate.
Biliary tract cancer (BTC)
Phase 1/2 enrolling as of January 2017.
Esophageal cancer
Phase 2 data due March 2019.
DKN-01 and Paclitaxel
Endometrial Cancer
Phase 1/2 trial to be initiated 1Q 2019.
TRX518 and avelumab
Solid tumors

Latest News

  1. Leap Therapeutics Inc (LPTX) CEO, President, Chairman Christopher Mirabelli Bought $999,999 of ...
  2. Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities
  3. Leap Therapeutics Announces Pricing of $11.5 Million Public Offering of Common Stock and Warrants
  4. Leap Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
  5. 2 Small-Cap Biotech Stocks That Are on My Radar
  6. Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX — Future Expectations, Projections Moving into 2019
  7. Leap Therapeutics Announces an Investigator-Initiated Study of DKN-01 in Patients with DKK1+ Advanced Prostate Cancer
  8. Leap Therapeutics Presents TRX518 Data at ESMO Immuno-Oncology Congress 2018 and Updated Data from DKN-01 Study in Biliary Tract Cancer
  9. Leap Therapeutics Reports Third Quarter 2018 Business Update and Financial Results
  10. Leap Therapeutics Presents Esophagogastric Cancer Data at SITC 2018 Annual Meeting
  11. Leap Therapeutics Presents Esophagogastric Cancer Data at ESMO 2018 Annual Congress
  12. Leap Therapeutics to Present Data from Study Evaluating DKN-01 in Combination with KEYTRUDA® (pembrolizumab) at the European Society of Medical Oncology 2018 Congress
  13. Leap Therapeutics to Present at Two October Conferences
  14. Leap Therapeutics to Participate in the H.C. Wainwright 20th Annual Global Investment Conference
  15. Leap Therapeutics Announces Collaboration with Pfizer and Merck